A new cost-saving in vivo shuttle session on syngeneic mouse tumor models

Explicyte is planning a new cost-effective in vivo shuttle session by end of February and thus provides an opportunity to speed up your new cancer therapy discovery process.

Want to screen efficacy on a series of syngeneic mouse tumor models or to challenge many of your therapeutics on a dedicated model? You can register below and get your study scheduled in February!


MCA205 sarcoma, 4T1 breast, CT26 colon, MC38 colon, EMT-6 breast, and Renca renal tumor-bearing mouse models exhibit various tumor growth profiles and differential responsiveness to PD1/PDL1 blockade.